BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12243110)

  • 1. Signal transduction inhibitors (STI571): molecularly targeted therapy.
    Corujo Y; Cáceres W
    P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
    Molnár L; Losonczy H
    Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical management of patients with chronic myeloid leukemia receiving imatinib.
    Deininger MW; O'Brien SG; Ford JM; Druker BJ
    J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N; Bossone G; Della Longa G; Di Cocco B
    Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].
    Jinnai I
    Nihon Rinsho; 2002 Jan; 60(1):88-94. PubMed ID: 11808344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
    Nadav L; Eldor A
    Harefuah; 2002 Feb; 141(2):158-62, 222. PubMed ID: 11905088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advancements in the treatment of chronic myelogenous leukemia.
    O'Dwyer ME; Mauro MJ; Druker BJ
    Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
    Hasselbalch HC
    Ugeskr Laeger; 2002 May; 164(22):2914-7. PubMed ID: 12082821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
    Etienne G; Mahon FX
    Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glivec and CML: a lucky date.
    Saglio G; Cilloni D; Rancati F; Boano L
    J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
    Nausová J; Priwitzerová M; Jarosová M; Indrák K; Faber E; Divoký V
    Cas Lek Cesk; 2006; 145(5):377-82. PubMed ID: 16755775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.